Candel Therapeutics, Inc. (CADL): debt financing — Candel Therapeutics secures $130M loan; reports positive CAN-3110 survival data

Candel Therapeutics, Inc.

Entered $130M term loan facility with Trinity Capital; $50M drawn at closing, up to $80M additional subject to milestones.
Cash and cash equivalents $87.2M as of Sept 30, 2025; loan carries 10.25% initial rate, 36-month interest-only period.
Phase 1b CAN-3110 interim data: median OS 11.8 months (arm A) and 12.0 months (arm B); two patients alive >40 months post-single injection.
Strategic pivot: seek external partnerships for CAN-2409 in PDAC; focus capital on early localized prostate cancer and NSCLC.
Proceeds to initiate phase 3 CAN-2409 trial in NSCLC in Q2 2026 and support BLA submission for prostate cancer planned Q4 2026.

item 1.01 item 2.02 item 2.03 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Candel Therapeutics, Inc. incurred term loan of aggregate principal amount of up to $130.0 million with lenders party thereto and Trinity Capital Inc., as administrative agent and collateral agent at the greater of (a) the sum of (i) The Wall Street Journal Prime Rate and (ii) 3. maturing October 1, 2030.

Instrument: term loan
Principal: aggregate principal amount of up to $130.0 million
Counterparty: lenders party thereto and Trinity Capital Inc., as administrative agent and collateral agent
Rate: the greater of (a) the sum of (i) The Wall Street Journal Prime Rate and (ii) 3.
Maturity: October 1, 2030
Event: incurrence

Exact text from the filing

(the “Agent”). Under the LSA, the Lenders agreed to extend debt capital to the Company, in the form of a term loan, in tranches totaling an aggregate principal amount of up to $130.0 million as follows: (a) at closing, the aggregate principal amount of $50.0 million (the “First Tranche”), (b) until May 30, 2027, subject to the achievement of certain regulatory,

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.4

Candel Therapeutics, Inc. issued 3.0% of the applicable draw of warrant to the Lenders (Trinity Capital Inc., as administrative agent and collateral agent).

Security: warrant
Shares: 3.0% of the applicable draw
Purchaser: the Lenders (Trinity Capital Inc., as administrative agent and collateral agent)

Exact text from the filing

The issuance of the Lender Warrants are exempt from the requirements of the Securities Act of 1933, as amended, pursuant to an exemption provided by Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder as transactions by an issuer not involving a public offering.

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-238254

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.